LV Diastolic Dysfunction Among the Patients With Systolic Heart Failure-clinical Significance and Prognostic Importance.
Launched by MEIR MEDICAL CENTER · May 2, 2010
Trial Information
Current as of May 27, 2025
Unknown status
Keywords
ClinConnect Summary
Recent studies have explored the prognostic role of TDI-derived parameters in major cardiac diseases, such as heart failure, acute myocardial infarction, and hypertension.(1-3). In these conditions, myocardial mitral annular or basal segmental (Sm) systolic and early diastolic (Ea or Em) velocities have been shown to predict mortality or cardiovascular events. In particular, those with reduced Sm or Em values of \<3 cm/s have a very poor prognosis. In heart failure and after myocardial infarction, noninvasive assessment of LV diastolic pressure by transmitral to mitral annular early diastol...
Gender
ALL
Eligibility criteria
- Summary of Subject Eligibility criteria:
- • Men and women \>18 years of age.
- • HF of\> 3 mo duration and NYHA class II, III, or IV at time of randomization.
- • LVEF \<45%
- • Blood pressure \<160/100
- • No HF primarily due to valvular heart disease and no clinically significant valvular heart disease that might lead to surgical correction within 12 months of randomization.
- • No implantable ICD or CRT within 30 days prior to randomization.
- • No chemo- or radio-therapy for treatment of a malignancy within 6 months prior to randomization or clinical evidence of current malignancy with the following exception: local BCC of the skin or cervical intraepithelial neoplasia.
- • Serum creatinine\<2.5 mg/dl
About Meir Medical Center
Meir Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent sponsor of clinical studies, Meir Medical Center is committed to fostering collaboration among healthcare professionals, researchers, and patients to explore new therapies and treatment modalities. With a focus on ethical practices and patient safety, the center aims to contribute significantly to the scientific community while enhancing the quality of care provided to its diverse patient population. Through its robust infrastructure and multidisciplinary approach, Meir Medical Center stands at the forefront of medical innovation, driving progress in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Korotinsky Svetlana, doctor
Principal Investigator
Israel: Clalit Health Services
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials